Trial reportPharmacogenomics2019
Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial.
Trial report in Pharmacogenomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.The pharmacogenomics journal · 2023Trial
- Challenges in pain management and opioid prescribing practices following traumatic injury: a focus group study with orthopedic surgeons and general practitioners.Scandinavian journal of primary health care · 2025Article
- Pharmacogenomics and Pharmacometabolomics in Precision Tramadol Prescribing for Enhanced Pain Management: Evidence from QBB and EMR Data.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The strong clinical interaction between bupropion and CYP2D6 is primarily mediated through bupropion metabolites and their stereoisomers: A paradigm for evaluating metabolites in drug-drug interaction risk.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- A software tool to adjust codeine dose based on CYP2D6 gene-pair polymorphisms and drug-drug interactions.The pharmacogenomics journal · 2023Review
- Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol.Pharmaceuticals (Basel, Switzerland) · 2023Article
- CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert opinion on drug metabolism & toxicology · 2022Review
- Clinical implementation of drug metabolizing gene-based therapeutic interventions worldwide.Human genetics · 2022Review
- Different Pharmacokinetics of Tramadol,Frontiers in pharmacology · 2021Article
- Barriers, solutions, and effect of using pharmacogenomics data to support opioid prescribing.Journal of managed care & specialty pharmacy · 2020Article
- Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing.Journal of personalized medicine · 2020Article
- Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug-Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients.Journal of personalized medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.